Changes in the Alignment of the Spine and Lower Limb in Children With Achondroplasia Treated With Vosoritide: A Single-center, 1-year Follow-up Prospective Study.

Sawamura K, Kitoh H, Kamiya Y, Mishima K, Matsushita M, Imagama S

Journal of pediatric orthopedics15 Apr 2025Cited by 6 (Europe PMC)

PMID40231376DOI10.1097/bpo.0000000000002980PepBankPUB-40231376

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study14

14 results from studies that gave the peptide. 14 results from people.

01HumanNon-randomized trialEfficacy outcome
In children with achondroplasia, height increased by 5.4±1.3 cm after vosoritide treatment compared with baseline.
In plain wordsIn children with achondroplasia receiving vosoritide, height increased from baseline.
Peptide
Vosoritide
Outcome
IncreaseHeight
Study
n = 17
Comparator
Before vosoritide treatment
Outcome group
Bone and joint · Musculoskeletal
Studied dose
Dose not stated · 1 yearAs given in this study (human).
Measurements
Mean height increase
5.4 cm
after 1 year of vosoritide versus before treatment; SD 1.3 as reported
Source sentences
Summary
After 1-year treatment of vosoritide, the mean height increased by 5.4±1.3 cm.
2 context sentences(design, population, supporting numbers)
Summary · context
This single-center, open-label, prospective study included patients with ACH aged younger than or equal to 15 years who received vosoritide treatment and had a minimum follow-up period of 1 year.
Summary · context
Seventeen patients (mean age, 7.6±2.7 y) were included.
Report a problemFND-4023137601
02HumanNon-randomized trialEfficacy outcome
In children with achondroplasia receiving vosoritide, cervical lordosis changed by 1.5 degrees from baseline.
In plain wordsIn children receiving vosoritide, cervical lordosis increased from baseline.
Peptide
Vosoritide
Outcome
IncreaseCervical lordosis
Study
n = 17
Comparator
Before vosoritide treatment
Outcome group
Bone and joint · Musculoskeletal
Studied dose
Dose not stated · 1 yearAs given in this study (human).
Measurements
Cervical lordosis change
1.5 degrees
after 1 year of vosoritide versus before treatment
Source sentences
Summary
Changes in spinal alignment after 1 year of vosoritide treatment were 1.5 degrees for cervical lordosis
2 context sentences(design, population, supporting numbers)
Summary · context
This single-center, open-label, prospective study included patients with ACH aged younger than or equal to 15 years who received vosoritide treatment and had a minimum follow-up period of 1 year.
Summary · context
Seventeen patients (mean age, 7.6±2.7 y) were included.
Report a problemFND-4023137602
03HumanNon-randomized trialEfficacy outcome
In children with achondroplasia receiving vosoritide, thoracic kyphosis changed by -1.3 degrees from baseline.
In plain wordsIn children receiving vosoritide, thoracic kyphosis decreased from baseline.
Peptide
Vosoritide
Outcome
DecreaseThoracic kyphosis
Study
n = 17
Comparator
Before vosoritide treatment
Outcome group
Bone and joint · Musculoskeletal
Studied dose
Dose not stated · 1 yearAs given in this study (human).
Measurements
Thoracic kyphosis change
−1.3 degrees
after 1 year of vosoritide versus before treatment
Source sentences
Summary
-1.3 degrees for thoracic kyphosis
2 context sentences(design, population, supporting numbers)
Summary · context
This single-center, open-label, prospective study included patients with ACH aged younger than or equal to 15 years who received vosoritide treatment and had a minimum follow-up period of 1 year.
Summary · context
Seventeen patients (mean age, 7.6±2.7 y) were included.
Report a problemFND-4023137603
04HumanNon-randomized trialEfficacy outcome
In children with achondroplasia receiving vosoritide, thoracolumbar kyphosis changed by -2.8 degrees from baseline.
In plain wordsIn children receiving vosoritide, thoracolumbar kyphosis decreased from baseline.
Peptide
Vosoritide
Outcome
DecreaseThoracolumbar kyphosis
Study
n = 17
Comparator
Before vosoritide treatment
Outcome group
Bone and joint · Musculoskeletal
Studied dose
Dose not stated · 1 yearAs given in this study (human).
Measurements
Thoracolumbar kyphosis change
−2.8 degrees
after 1 year of vosoritide versus before treatment
Source sentences
Summary
-2.8 degrees for thoracolumbar kyphosis
2 context sentences(design, population, supporting numbers)
Summary · context
This single-center, open-label, prospective study included patients with ACH aged younger than or equal to 15 years who received vosoritide treatment and had a minimum follow-up period of 1 year.
Summary · context
Seventeen patients (mean age, 7.6±2.7 y) were included.
Report a problemFND-4023137604
05HumanNon-randomized trialEfficacy outcome
In children with achondroplasia receiving vosoritide, lumbar lordosis changed by -5.2 degrees and moved significantly towards normal.
In plain wordsIn children receiving vosoritide, lumbar lordosis decreased significantly towards normal compared with baseline.
Peptide
Vosoritide
Outcome
DecreaseLumbar lordosis
Study
n = 17
Comparator
Before vosoritide treatment
Outcome group
Bone and joint · Musculoskeletal
Studied dose
Dose not stated · 1 yearAs given in this study (human).
Measurements
Lumbar lordosis change
−5.2 degrees
after 1 year of vosoritide versus before treatment; statistically significant change towards normal
Source sentences
Summary
-5.2 degrees for lumbar lordosis (LL)
3 context sentences(design, population, supporting numbers)
Summary · context
The LL, MAA, mLPFA, and mLDFA levels showed statistically significant changes towards the normal range after treatment.
Summary · context
This single-center, open-label, prospective study included patients with ACH aged younger than or equal to 15 years who received vosoritide treatment and had a minimum follow-up period of 1 year.
Summary · context
Seventeen patients (mean age, 7.6±2.7 y) were included.
Report a problemFND-4023137605
06HumanNon-randomized trialEfficacy outcome
In children with achondroplasia receiving vosoritide, pelvic tilt changed by -2.2 degrees from baseline.
In plain wordsIn children receiving vosoritide, pelvic tilt decreased from baseline.
Peptide
Vosoritide
Outcome
DecreasePelvic tilt
Study
n = 17
Comparator
Before vosoritide treatment
Outcome group
Bone and joint · Musculoskeletal
Studied dose
Dose not stated · 1 yearAs given in this study (human).
Measurements
Pelvic tilt change
−2.2 degrees
after 1 year of vosoritide versus before treatment
Source sentences
Summary
-2.2 degrees for pelvic tilt
2 context sentences(design, population, supporting numbers)
Summary · context
This single-center, open-label, prospective study included patients with ACH aged younger than or equal to 15 years who received vosoritide treatment and had a minimum follow-up period of 1 year.
Summary · context
Seventeen patients (mean age, 7.6±2.7 y) were included.
Report a problemFND-4023137606
07HumanNon-randomized trialEfficacy outcome
In children with achondroplasia receiving vosoritide, pelvic incidence changed by -2.6 degrees from baseline.
In plain wordsIn children receiving vosoritide, pelvic incidence decreased from baseline.
Peptide
Vosoritide
Outcome
DecreasePelvic incidence
Study
n = 17
Comparator
Before vosoritide treatment
Outcome group
Bone and joint · Musculoskeletal
Studied dose
Dose not stated · 1 yearAs given in this study (human).
Measurements
Pelvic incidence change
−2.6 degrees
after 1 year of vosoritide versus before treatment
Source sentences
Summary
-2.6 degrees for pelvic incidence
2 context sentences(design, population, supporting numbers)
Summary · context
This single-center, open-label, prospective study included patients with ACH aged younger than or equal to 15 years who received vosoritide treatment and had a minimum follow-up period of 1 year.
Summary · context
Seventeen patients (mean age, 7.6±2.7 y) were included.
Report a problemFND-4023137607
08HumanNon-randomized trialEfficacy outcome
In children with achondroplasia receiving vosoritide, sacral slope changed by -0.4 degrees from baseline.
In plain wordsIn children receiving vosoritide, sacral slope decreased from baseline.
Peptide
Vosoritide
Outcome
DecreaseSacral slope
Study
n = 17
Comparator
Before vosoritide treatment
Outcome group
Bone and joint · Musculoskeletal
Studied dose
Dose not stated · 1 yearAs given in this study (human).
Measurements
Sacral slope change
−0.4 degrees
after 1 year of vosoritide versus before treatment
Source sentences
Summary
-0.4 degrees for sacral slope
2 context sentences(design, population, supporting numbers)
Summary · context
This single-center, open-label, prospective study included patients with ACH aged younger than or equal to 15 years who received vosoritide treatment and had a minimum follow-up period of 1 year.
Summary · context
Seventeen patients (mean age, 7.6±2.7 y) were included.
Report a problemFND-4023137608
09HumanNon-randomized trialEfficacy outcome
In children with achondroplasia receiving vosoritide, C7 sagittal vertical axis changed by 2.6 mm from baseline.
In plain wordsIn children receiving vosoritide, C7 sagittal vertical axis increased from baseline.
Peptide
Vosoritide
Outcome
IncreaseC7 sagittal vertical axis
Study
n = 17
Comparator
Before vosoritide treatment
Outcome group
Bone and joint · Musculoskeletal
Studied dose
Dose not stated · 1 yearAs given in this study (human).
Measurements
C7 sagittal vertical axis change
2.6 mm
after 1 year of vosoritide versus before treatment
Source sentences
Summary
2.6 mm for C7 sagittal vertical axis.
2 context sentences(design, population, supporting numbers)
Summary · context
This single-center, open-label, prospective study included patients with ACH aged younger than or equal to 15 years who received vosoritide treatment and had a minimum follow-up period of 1 year.
Summary · context
Seventeen patients (mean age, 7.6±2.7 y) were included.
Report a problemFND-4023137609
10HumanNon-randomized trialEfficacy outcome
In children with achondroplasia receiving vosoritide, mechanical axis angle changed by -3.4 degrees and moved significantly towards normal.
In plain wordsIn children receiving vosoritide, mechanical axis angle decreased significantly towards normal compared with baseline.
Peptide
Vosoritide
Outcome
DecreaseMechanical axis angle
Study
n = 17
Comparator
Before vosoritide treatment
Outcome group
Bone and joint · Musculoskeletal
Studied dose
Dose not stated · 1 yearAs given in this study (human).
Measurements
Mechanical axis angle change
−3.4 degrees
after 1 year of vosoritide versus before treatment; statistically significant change towards normal
Source sentences
Summary
Alignment changes in the lower limbs were -3.4 degrees for mechanical axis angle (MAA)
3 context sentences(design, population, supporting numbers)
Summary · context
The LL, MAA, mLPFA, and mLDFA levels showed statistically significant changes towards the normal range after treatment.
Summary · context
This single-center, open-label, prospective study included patients with ACH aged younger than or equal to 15 years who received vosoritide treatment and had a minimum follow-up period of 1 year.
Summary · context
Seventeen patients (mean age, 7.6±2.7 y) were included.
Report a problemFND-4023137610
11HumanNon-randomized trialEfficacy outcome
In children with achondroplasia receiving vosoritide, mechanical lateral proximal femoral angle changed by 1.7 degrees and moved significantly towards normal.
In plain wordsIn children receiving vosoritide, the proximal femoral angle increased significantly towards normal compared with baseline.
Peptide
Vosoritide
Outcome
IncreaseMechanical lateral proximal femoral angle
Study
n = 17
Comparator
Before vosoritide treatment
Outcome group
Bone and joint · Musculoskeletal
Studied dose
Dose not stated · 1 yearAs given in this study (human).
Measurements
Mechanical lateral proximal femoral angle change
1.7 degrees
after 1 year of vosoritide versus before treatment; statistically significant change towards normal
Source sentences
Summary
1.7 degrees for mechanical lateral proximal femoral angle (mLPFA)
3 context sentences(design, population, supporting numbers)
Summary · context
The LL, MAA, mLPFA, and mLDFA levels showed statistically significant changes towards the normal range after treatment.
Summary · context
This single-center, open-label, prospective study included patients with ACH aged younger than or equal to 15 years who received vosoritide treatment and had a minimum follow-up period of 1 year.
Summary · context
Seventeen patients (mean age, 7.6±2.7 y) were included.
Report a problemFND-4023137611
12HumanNon-randomized trialEfficacy outcome
In children with achondroplasia receiving vosoritide, mechanical lateral distal femoral angle changed by -2.8 degrees and moved significantly towards normal.
In plain wordsIn children receiving vosoritide, the distal femoral angle decreased significantly towards normal compared with baseline.
Peptide
Vosoritide
Outcome
DecreaseMechanical lateral distal femoral angle
Study
n = 17
Comparator
Before vosoritide treatment
Outcome group
Bone and joint · Musculoskeletal
Studied dose
Dose not stated · 1 yearAs given in this study (human).
Measurements
Mechanical lateral distal femoral angle change
−2.8 degrees
after 1 year of vosoritide versus before treatment; statistically significant change towards normal
Source sentences
Summary
-2.8 degrees for mechanical lateral distal femoral angle (mLDFA)
3 context sentences(design, population, supporting numbers)
Summary · context
The LL, MAA, mLPFA, and mLDFA levels showed statistically significant changes towards the normal range after treatment.
Summary · context
This single-center, open-label, prospective study included patients with ACH aged younger than or equal to 15 years who received vosoritide treatment and had a minimum follow-up period of 1 year.
Summary · context
Seventeen patients (mean age, 7.6±2.7 y) were included.
Report a problemFND-4023137612
13HumanNon-randomized trialEfficacy outcome
In children with achondroplasia receiving vosoritide, medial proximal tibial angle changed by -0.2 degrees from baseline.
In plain wordsIn children receiving vosoritide, the medial proximal tibial angle decreased from baseline.
Peptide
Vosoritide
Outcome
DecreaseMedial proximal tibial angle
Study
n = 17
Comparator
Before vosoritide treatment
Outcome group
Bone and joint · Musculoskeletal
Studied dose
Dose not stated · 1 yearAs given in this study (human).
Measurements
Medial proximal tibial angle change
−0.2 degrees
after 1 year of vosoritide versus before treatment
Source sentences
Summary
-0.2 degrees for medial proximal tibial angle
2 context sentences(design, population, supporting numbers)
Summary · context
This single-center, open-label, prospective study included patients with ACH aged younger than or equal to 15 years who received vosoritide treatment and had a minimum follow-up period of 1 year.
Summary · context
Seventeen patients (mean age, 7.6±2.7 y) were included.
Report a problemFND-4023137613
14HumanNon-randomized trialEfficacy outcome
In children with achondroplasia receiving vosoritide, lateral distal tibial angle changed by -0.5 degrees from baseline.
In plain wordsIn children receiving vosoritide, the lateral distal tibial angle decreased from baseline.
Peptide
Vosoritide
Outcome
DecreaseLateral distal tibial angle
Study
n = 17
Comparator
Before vosoritide treatment
Outcome group
Bone and joint · Musculoskeletal
Studied dose
Dose not stated · 1 yearAs given in this study (human).
Measurements
Lateral distal tibial angle change
−0.5 degrees
after 1 year of vosoritide versus before treatment
Source sentences
Summary
-0.5 degrees for lateral distal tibial angle.
2 context sentences(design, population, supporting numbers)
Summary · context
This single-center, open-label, prospective study included patients with ACH aged younger than or equal to 15 years who received vosoritide treatment and had a minimum follow-up period of 1 year.
Summary · context
Seventeen patients (mean age, 7.6±2.7 y) were included.
Report a problemFND-4023137614

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
28 Oct 2026, 02:03 UTC
Study results updated
Version 1
27 Oct 2026, 16:37 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

Journal Article

MeSH terms

Keywords

PepBank is a research reference. Talk to a doctor before you use any peptide.